Literature DB >> 10588927

PF9404C, a new slow NO donor with beta receptor blocking properties.

M Villarroya1, C J Herrero, A Ruíz-Nuño, R de Pascual, M del Valle, P Michelena, M Grau, E Carrasco, M G López, A G García.   

Abstract

1. PF9404C is the S-S diesteroisomer of a novel blocker of beta adrenergic receptors with vasodilatory properties. It causes a concentration-dependent relaxation of rat aorta helical strips pre-contracted with 10(-6) M noradrenaline (NA; IC(50) 33 nM). It was equipotent to nitroglycerin (NTG; IC(50) 49 nM), but much more potent than isosorbide dinitrate (ISD; IC(50) 15,000 nM). 2. Oxyhaemoglobin (10 microM) shifted to the right the concentration-response curve for the relaxation induced by PF9404C (IC(50) 530 nM) or NTG (IC(50) 61 nM). 3. Either methylene blue (MB) or ODQ (1 microM each) largely prevented the vasorelaxing responses to increasing concentrations of PF9404C or NTG. 4. In rat aorta smooth muscle cells, PF9404C increased the formation of cyclic GMP from 3 pmol mg(-1) protein in basal conditions, to 53 pmol mg(-1) protein in 10 microM PF9404C. Neither metoprolol nor carvedilol enhanced cyclic GMP. 5. In the electrically driven guinea-pig left atrium, PF9404C blocked the inotropic effects of isoprenaline in a concentration-dependent manner. Its IC(50) (30 nM) was similar to that for S-propranolol (22.4 nM) and lower than the IC(50)s for metoprolol (120 nM) and atenolol (192 nM). The beta-adrenergic ligand (-)-[(3)H]-CGP12177 (0.2 nM) was displaced from its binding to rat brain membranes with K(i) of 7 nM, 17 nM, 170 nM and 1.2 microM respectively for PF9404C, S-(-)propranolol, metoprolol, and atenolol. 6. The data are consistent with the idea that the S-S diesteroisomer PF9404C, is a potent vasorelaxing agent, as well as a blocker of cardiac beta adrenergic receptors. The mechanism of its vasorelaxing effects involves the slow generation of NO. This molecule can, therefore, exhibit antihypertensive and cardioprotective actions through a double mechanism, NO donation and beta blockade.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10588927      PMCID: PMC1571821          DOI: 10.1038/sj.bjp.0702992

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  Activation of cerebral guanylate cyclase by nitric oxide.

Authors:  N Miki; Y Kawabe; K Kuriyama
Journal:  Biochem Biophys Res Commun       Date:  1977-04-25       Impact factor: 3.575

Review 2.  Guanylate cyclase: activation by azide, nitro compounds, nitric oxide, and hydroxyl radical and inhibition by hemoglobin and myoglobin.

Authors:  F Murad; C K Mittal; W P Arnold; S Katsuki; H Kimura
Journal:  Adv Cyclic Nucleotide Res       Date:  1978

3.  Possible involvement of S-nitrosothiols in the activation of guanylate cyclase by nitroso compounds.

Authors:  L J Ignarro; J C Edwards; D Y Gruetter; B K Barry; C A Gruetter
Journal:  FEBS Lett       Date:  1980-02-11       Impact factor: 4.124

4.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

Review 5.  Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D McTavish; D Campoli-Richards; E M Sorkin
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

6.  Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.

Authors:  C D Furberg; B M Psaty; J V Meyer
Journal:  Circulation       Date:  1995-09-01       Impact factor: 29.690

7.  Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one.

Authors:  J Garthwaite; E Southam; C L Boulton; E B Nielsen; K Schmidt; B Mayer
Journal:  Mol Pharmacol       Date:  1995-08       Impact factor: 4.436

8.  cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase.

Authors:  M A Moro; R J Russel; S Cellek; I Lizasoain; Y Su; V M Darley-Usmar; M W Radomski; S Moncada
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

9.  The risk of myocardial infarction associated with antihypertensive drug therapies.

Authors:  B M Psaty; S R Heckbert; T D Koepsell; D S Siscovick; T E Raghunathan; N S Weiss; F R Rosendaal; R N Lemaitre; N L Smith; P W Wahl
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272

10.  Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells.

Authors:  T L Yue; P J Mckenna; J L Gu; H Y Cheng; R R Ruffolo; G Z Feuerstein
Journal:  Hypertension       Date:  1993-12       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.